Table 4.
Median survival (months) in the 145 patients with "early" HCC of the internal validation analysis according to the type of treatment.
| Type of treatment | N | Median survival (months) | CI 95% | |
|---|---|---|---|---|
| OLTx | 5 | 79 | 66.211 | 91.556 |
| RESECTION | 17 | 45 | 34,327 | 53,254 |
| RFTA | 46 | 45 | 40.394 | 51.247 |
| PEI | 16 | 37 | 14.384 | 59.616 |
| TACE | 41 | 44 | 34.518 | 53.482 |
| PEI + TACE | 10 | 36 | 32.006 | 39.994 |
| BSC | 10 | 12 | 9.078 | 14.922 |
| Total | 145 | 45 | 40.708 | 49.292 |
OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; BSC: best supportive care.
The difference in survival among treatment groups is statistically significant (p = 0,003). In the COX multivariate analysis however only age and Child-Pugh class (p = 0.025 and p = 0.011, respectively) were selected as independent predictors of survival.